Business Context and Reporting Period
Propanc Biopharma, Inc. filed a Form 8-K Current Report on December 10, 2020, regarding a material definitive agreement entered into on that date. The Company, incorporated in Delaware with principal offices in Australia, operates in the biopharma sector and trades on the OTC Pink market under the symbol PPCB.
Key Financial Metrics and Transaction Details
The filing details a financing transaction rather than periodic financial performance metrics. Key figures include:
- Principal Amount: $131,000 (Convertible Redeemable Promissory Note).
- Net Proceeds: $125,000 intended for general working capital.
- Transaction Costs: $6,000 paid to the investor for legal fees and expenses.
- Interest Rate: 8% per annum, payable in cash or shares upon maturity or acceleration.
- Maturity Date: December 10, 2021.
Material Changes and Terms
The Company entered into a Securities Purchase Agreement with GW Holdings Group, LLC ("GW"). The note includes specific conversion and redemption features:
- Conversion Option: GW may convert the principal into common stock starting June 18, 2021, at a 40% discount to the lowest closing bid price of the prior ten trading days.
- Ownership Cap: Conversion is limited to prevent GW and affiliates from beneficially owning more than 4.99% of outstanding shares, unless increased to 9.99% with 61 days' prior notice.
- Redemption Penalties: The Company may redeem the note early with escalating penalties: 115% of face value (days 1-60), 125% (days 61-120), or 135% (days 121-180), plus accrued interest.
- Default: The note becomes immediately due upon default events, including insolvency or failure to issue shares upon conversion notice.
Guidance, Risks, and Unusual Items
The filing does not provide forward-looking guidance, revenue outlook, or management commentary on operational performance. The transaction was executed as an unregistered private placement under Section 4(a)(2) of the Securities Act, relying on the investor being an accredited investor and the transaction being isolated. The primary risk highlighted is the potential dilution of existing shareholders upon conversion and the obligation to pay significant redemption premiums if the Company chooses to repay the debt early.
Investor Verification Checklist
- Verify the current share count to assess the potential dilution impact of the 40% discount conversion feature.
- Confirm the Company's current cash position to evaluate the ability to service the 8% interest or redeem the note if necessary.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and the Promissory Note (Exhibit 4.1) for additional covenants not summarized in the 8-K.
- Monitor the stock price volatility, as the conversion price is tied to the lowest closing bid of the prior ten trading days.